Abstract 111P
Background
The integration of molecular profiling (MP) into clinical practice faces some challenges, particularly in Ukraine where war-related restrictions and logistical issues complicate the access to international laboratories. Inadequate sample quality and a lack of expertise also make the local implementation of MP difficult. This study explores the feasibility and efficiency of molecular profiling for cancer patients in Ukraine where these barriers limit treatment options.
Methods
MP was conducted using OncoMine Comprehensive Plus assay (Thermo) to analyze genetic alterations in 51 patients (29 women, 22 men, mean age 51). The average TAT for results was eight working days: 63% results within 2 weeks and 86% within 3 weeks. According to 2024 ESMO NGS guidelines, patients with eight types of cancers were tested, namely CRC, NSCLC, ovarian cancer, breast carcinoma, sarcoma, cholangiocarcinoma, and CUP.
Results
Valid results were obtained in 90% of cases for single-gene markers and in 50% for genomic markers. 36 (71%) patients had actionable genetic alterations for targeted therapies or immunotherapy. 15 (29%) patients had no clear therapeutic options. According to OncoKB system, 18 (35%) alterations were classified as OncoKB 1-2 (BRAF V600E (4), BRCA1/2 (3), EGFR (1), IDH1 (3), LOH-High (5), NTRK (1), PIK3CA (1), TMB-High (5)) and 18 (35%) had treatment options with lower OncoKB level of evidence. Additionally, 7 (14%) patients had potentially germline mutations requiring genetic counseling.
Conclusions
Therapeutically significant markers were found in 71% of patients, 50% among those level 1 or 2 according to OncoKB. The study stresses the importance of a multidisciplinary team approach to applying molecular data in clinical practice, which can improve treatment outcomes and patient prognoses in Ukraine.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Study group.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.